Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Impact of HER4 expression on the overall survival (OS) and disease-free survival (DFS) in tamoxifen-treated patients stratified by menopausal status

From: HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women

Strata Predictor OS DFS
HR 95% CI p value HR 95% CI p value
Premenopausal (< 46 years) HER4 continuous 1.06 0.59 1.89 0.845 0.77 0.43 1.38 0.380
HER4 ≥ 1 (ref. HER4 < 1) 1.51 0.25 9.01 0.655 0.56 0.15 2.03 0.377
Postmenopausal (≥ 46 years HER4 continuous 1.43 1.09 1.86 0.009 1.81 1.25 2.63 0.002
HER4 ≥ 1 (ref. HER4 < 1) 4.98 1.32 18.80 0.018 2.94 0.96 9.00 0.059
  1. Significant values are shows in bold typeface
  2. CI confidence interval, HR hazard ratio